Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors

• Main Authors: Xi-xi Hou (Author), Xiao-qing Gong (Author), Long-fei Mao (Author), Ge Sun (Author), Jian-xue Yang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug resistance during chemotherapy. Indoleamine 2,3-dioxyg...